Oprah and Semaglutide

Oprah Winfrey Criticizes Her Past Weight-Loss Methods

Oprah Winfrey recently condemned her previous approaches to weight loss during WeightWatchers’ three-hour “Making the Shift” live event on Thursday. The former television host admitted she had been “a steadfast participant in this diet culture” for decades.

Acknowledging Past Actions

Winfrey reflected on her influence over the years: “Through my platforms, through the magazine, through the talk show for 25 years and online. I’ve been a major contributor to it. I cannot tell you how many weight-loss shows and makeovers I have done, and they have been a staple since I’ve been working in television.”

Winfrey, who served on WeightWatchers’ board of directors for nearly a decade and was a prominent spokesperson for the brand, joined a lineup of guest speakers including Rebel Wilson, Busy Phillips, Amber Riley, and WeightWatchers CEO Sima Sistani.

Regrets from the Past

During the event, Winfrey recalled a particularly troubling moment from her talk show when she presented a red Radio Flyer wagon filled with 67 pounds of fat to demonstrate her weight loss after months of a liquid-only fast.

“I’ve shared how that famous wagon of fat moment on the ‘Oprah’ show is one of my biggest regrets,” she said. “It sent a message that starving yourself with a liquid diet set a standard for people watching that I nor anybody else could uphold.”

She added, “The very next day, I began to gain the weight back. Maya Angelou always said, ‘When you know better, you do better.’ So, these conversations, for me, are an effort to do better. I own what I’ve done, and I now want to do better.”

Struggles with Diet Culture

Winfrey noted that her struggle with “yo-yo diet moments” made her a “national joke.” The WeightWatchers event highlighted the company’s shift from promoting diet culture to supporting members, including those using weight-loss medications like Ozempic and Wegovy.

Embracing Medication

In December, Winfrey revealed that she had turned to weight-loss medication, semaglutide, “as a tool” to achieve a slimmer figure after previously refusing to share this information.

Reflecting on public scrutiny about her weight, Winfrey told People, “I didn’t feel angry. I felt sad. I felt hurt. I swallowed the shame. I accepted that it was my fault. It was public sport to make fun of me for 25 years. I have been blamed and shamed, and I blamed and shamed myself.”

Winfrey’s weight had occupied “five decades of space in my brain, yo-yoing and feeling like ‘why can’t I just conquer this thing,’ believing willpower was my failing.”

A Shift in Perspective

During a panel discussion for her website, Oprah Daily, she realized she shouldn’t have been so harsh on herself. “When I first started hearing about the weight loss drugs, at the same time, I was going through knee surgery, and I felt, ‘I’ve got to do this on my own.’ Because if I take the drug, that’s the easy way out.”

She explained, “I realized I’d been blaming myself all these years for being overweight, and I have a predisposition that no amount of willpower is going to control. Obesity is a disease. It’s not about willpower — it’s about the brain.”

Winfrey’s doctor then prescribed her a medication, which she chose not to name. She described the availability of medically approved prescriptions for managing weight as a “relief, like redemption, like a gift.”

Moving Forward

After announcing her use of medication to aid in weight loss, Winfrey stepped down from the WeightWatchers board of directors after nearly a decade. “I’m absolutely done with the shaming from other people and particularly myself,” she concluded.

Injectable Weight Loss Drugs

wegovy price in india

Injectable Weight Loss Drugs: Usage and Effectiveness

High Levels of Effectiveness Reported, But Less So Among Older Users

Overview

WASHINGTON, D.C. — Six percent of U.S. adults, representing approximately 15.5 million people, report using injectable diabetes medication for weight loss, with 3% currently using such medication specifically for this purpose. Usage rates are slightly higher among women, those with health insurance, and individuals aged 40 to 64.

Study Details

This analysis is part of the Gallup National Health and Well-Being Index. The results are based on a web survey of 5,577 U.S. adults, conducted March 4-9, 2024, using Gallup’s probability-based panel encompassing all 50 states and the District of Columbia.

Since the U.S. Food and Drug Administration approved the Eli Lilly drug Wegovy for weight loss in 2021, the use of diabetic drugs containing semaglutide has gained popularity among those hoping to lose weight. Other options have since entered the market, including Zepbound (tirzepatide), which received FDA approval in November 2023.

Gallup measured current or previous household use by asking: “Have you or a family member ever taken an injection for weight loss, such as semaglutide (brand names Ozempic and Wegovy) or liraglutide (brand name Saxenda)?” To measure current individual use, they asked: “Are you currently taking injections for weight loss, such as semaglutide (brand names Ozempic and Wegovy) or liraglutide (brand name Saxenda)?” The data reported here are based on individual rates rather than household.

Effectiveness Among Different Age Groups

Close to two-thirds of Americans who have taken weight loss injections (64%) say the drugs have been either “extremely effective” or “effective” in helping them lose weight. Only 11% report the injections as “not at all effective.”

Perceived effectiveness is relatively consistent among younger and middle-aged adults, with 70% of those aged 18 to 49 and 67% of those aged 50 to 64 reporting weight loss injections as effective or extremely effective. However, among adults aged 65 and older, reported effectiveness drops to 48%.

Higher Disease Burden Among Users

Both current and past users of weight loss injections are more likely to be obese compared to those who have never used the injections. Current users are about twice as likely to be obese (71%) compared to non-users (36%).

Chronic conditions such as high blood pressure, high cholesterol, and diabetes are also substantially higher among both current and past users than among non-users, indicating a higher overall disease burden among users.

Compared to current users, past users report lower levels of obesity, high blood pressure, high cholesterol, and diabetes. These differences align with clinical trial benefits, suggesting that weight loss injections prescribed alongside diet and exercise changes may help reduce disease burden.

Greater Benefits Reported by Current Users

Current users are more optimistic about their weight loss and wellbeing than past users. Nearly three-quarters of current users (73%) say weight loss injections are effective or extremely effective, compared with 53% of past users.

Lower levels of effectiveness may contribute to the decision to discontinue use. Additionally, less positive reports among past users align with critiques of weight loss injections as a long-term solution, with indications that discontinued use can lead to weight gain or other side effects.

Implications

The reported effectiveness among users of injectable weight loss drugs suggests that a substantial number of Americans — about 10 million — believe they have benefited from the injections. Evidence of lower rates of obesity and other chronic conditions among past users relative to current users supports these reports.

However, lower self-reported effectiveness among older adults and past users, as well as lower usage rates among uninsured Americans, highlight the need for further exploration of access and benefits across various subgroups.

Most Popular Prescription Drugs 2023

The Most Popular Prescription Drugs in the U.S. for 2023

We all know what’s in our medicine cabinet — but how does it compare with others?

The American Society of Health-System Pharmacists recently used data from drug manufacturers to determine the most popular prescription drugs in the U.S. based on spending in 2023.

Key Trends in Prescription Drug Spending

Weight-loss drugs were the main drivers of a 13.5% increase in prescription drug spending in the U.S. Tizepatide, initially a diabetes treatment, grew 373% in popularity, even though the FDA did not approve it for weight loss until late 2023. Conversely, hospital spending on prescription drugs decreased by 1.1% in 2023.

The American Society of Health-System Pharmacists speculates that spending on weight-loss drugs will continue to rise as supply meets the growing demand.

Top Prescription Drugs by Spending

The following drugs each accounted for more than $10 billion in U.S. spending in 2023, including spending at pharmacies, clinics, and hospitals.

11. Risankizumab (Skyrizi)

Amount spent: $10.1 billion in 2023

Risankizumab is used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn’s disease. It can be administered as an injection or a pill.

10. Dupilumab (Dupixent)

Amount spent: $11.49 billion in 2023

Dupilumab is an injection for people with eczema who have not responded to other treatments. It is also used to treat certain types of asthma.

9. Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy)

Amount spent: $13.15 billion in 2023

Biktarvy is a single-pill treatment for HIV infection. It does not cure HIV but helps reduce the risk of developing AIDS and HIV-related illnesses.

Sunny Pharma link: Sunny Pharma Biktarvy Generic

8. Tirzepatide (Mounjaro, Zepbound)

Amount spent: $13.16 billion in 2023

Tirzepatide, known as Mounjaro for Type 2 diabetes treatment, was approved as Zepbound for weight management in late 2023.

Sunny Pharma link: Sunny Pharma Tirzepatide Generic

7. Pembrolizumab (Keytruda)

Amount spent: $15.4 billion in 2023

Pembrolizumab is an injection used to treat various types of skin cancer and other forms of cancer, often in combination with chemotherapy.

6. Ustekinumab (Stelara)

Amount spent: $15.87 billion in 2023

Ustekinumab treats psoriatic arthritis, plaque psoriasis, and Crohn’s disease. It is administered via injection.

5. Empagliflozin (Jardiance)

Amount spent: $15.89 billion in 2023

Empagliflozin lowers blood sugar levels in Type 2 diabetes and reduces the risk of cardiovascular events and worsening kidney disease.

Sunny Pharma link: Sunny Pharma Empagliflozin Generic

4. Dulaglutide (Trulicity)

Amount spent: $16.28 billion in 2023

Dulaglutide is a weekly injection for Type 2 diabetes that also helps reduce the risk of heart attack and stroke.

3. Apixaban (Eliquis)

Amount spent: $22.11 billion in 2023

Apixaban treats and prevents deep venous thrombosis and pulmonary embolism and helps prevent strokes in patients with certain heart conditions.

2. Adalimumab (Humira)

Amount spent: $35.33 billion in 2023

Adalimumab treats a variety of autoimmune conditions, including rheumatoid arthritis, psoriasis, and Crohn’s disease.

1. Semaglutide (Ozempic, Rybelsus, Wegovy)

Amount spent: $38.58 billion in 2023

Semaglutide, marketed as Ozempic, Rybelsus, and Wegovy, is used to treat Type 2 diabetes and as a weight-loss aid. Its popularity has surged due to its effectiveness in weight management.

Semaglutide Buy Online: Sunny Pharma Semaglutide Generic

By understanding these trends and the significant spending on these medications, we can better appreciate the dynamics of the U.S. pharmaceutical market and the growing emphasis on treatments for chronic conditions and weight management.

Maryland Board Drops Biktarvy Review

Maryland Board Names Six Drugs for Cost Review to Address Affordability

A Maryland board dedicated to controlling prescription drug costs has officially named six medications for “cost review” to determine if these drugs pose affordability challenges for residents on the state’s health care plan. Notably, drugs treating attention-deficit/hyperactivity disorder (ADHD) and HIV/AIDS did not make the list for now.

Prescription Drug Affordability Board’s Decision

The Prescription Drug Affordability Board (PDAB) finalized the selected drugs for review at an in-person meeting, marking a shift from years of virtual meetings due to COVID-19 precautions.

“It’s nice to see our board members and our new employees,” said board Chair Van T. Mitchell from the William Amoss meeting room in the Miller Senate Office Building. “We finally, I think, are moving in the right direction with a lot of momentum.”

Challenges and Legislative Support

Virtual meetings were just one of the hurdles the board faced. Created by the General Assembly in 2019, the board’s operations were delayed, partly due to a veto from former Gov. Larry Hogan amid pandemic-induced economic uncertainty in 2020. Gov. Wes Moore signed legislation in 2023 reaffirming the board’s authority to issue upper payment limits as a potential cost-reduction tool and extended deadlines from the earlier law.

Progress Despite Initial Delays

“It’s been taking us a while to get to where we need to,” board member Stephen Rockower, a retired orthopedic surgeon, said after Monday’s meeting. “Some of it was us getting ourselves organized and getting the funding from the state to be able to do what we needed to do. But now that we’ve done that … we’re making progress.”

Selected Drugs for Cost Review

Monday’s meeting marked the first time a handful of drugs will officially undergo “cost review.” Over the next 60 days, board staff will seek public comments, additional information, and data to determine if Marylanders struggle to afford treatments for diabetes, moderate-to-severe eczema, and other conditions treated by the targeted medications.

Diabetes and Eczema Medications

Four drugs treating Type 2 diabetes were prioritized for cost-review analysis: Ozempic, Trulicity, Farxiga, and Jardiance. The latter two are also used to treat heart and kidney disease. Ozempic is additionally used as a weight-loss treatment for certain patients. Skyrizi, used to treat plaque psoriasis and Crohn’s disease, was also selected for the first round of review. Dupixent, used to treat moderate-to-severe eczema, was selected for cost review as a lower priority, meaning the board will conduct its analysis of Dupixent after the other five drugs.

Excluded Drugs: Biktarvy and Vyvanse

Initially, there were eight prescription drugs being considered for review, but two were removed from consideration for now: Biktarvy and Vyvanse.

Biktarvy is a single-pill treatment that manages the symptoms of HIV. PDAB member Gerard Anderson argued that federal assistance programs to help low-income patients afford Biktarvy could complicate the board’s ability to collect data on the drug’s affordability.

“We would essentially have to figure out how to deal with the many different components of the federal and state government and local governments,” Anderson advised. “That, to me, is the real challenge here, dealing with Biktarvy.”

The ADHD treatment Vyvanse did not make the cost-review cut for similar reasons. Board member Joseph Levy indicated that focusing on less complex drugs initially is acceptable, but more complicated drugs could be considered in the future.

Sunny Pharma’s Biktarvy Generic

Amid these developments, it’s noteworthy that Sunny Pharma is producing a generic version of Biktarvy. This could potentially offer a more affordable option for HIV treatment, reducing financial barriers for many patients. However, the PDAB did not include this generic in the current cost review, leaving the door open for future consideration.

Moving Forward

Vincent DeMarco, a healthcare advocate and longtime supporter of the board, called Monday’s meeting “historic” for its progress. “They’re making some substantial progress. We understand that this is not an easy thing.”

Andrew York, the board’s executive director, emphasized that the selection is not a declaration of unaffordability but an opportunity to gather more information on out-of-pocket costs and other financial considerations.

Next Steps

The next PDAB meeting is scheduled for July 22 and is expected to be in-person again. The board hopes to discuss the findings of the cost review study at that meeting.

Josh Gates’ Experience with Semaglutide

semaglutide buy online

The Cost and Impact of a Viral Drug

Introduction

Josh Gates, known for his insightful explorations and compelling storytelling, decided to embark on a personal journey in 2019 with a new drug promising to help him lose weight by reducing his appetite. This drug, Ozempic, which has the generic name semaglutide, caught his attention due to its potential benefits. However, the experience was not as smooth as he anticipated.

Initial Enthusiasm and Side Effects

Upon starting the injection-based drug, Gates initially found the results astonishing. “The first week or so, I was thinking, ‘This is astonishing,’” he shared. “Not only do I not want to eat, I don’t want any alcohol of any kind. This is going to be brilliant.”

However, his enthusiasm quickly waned as he began experiencing severe side effects. “I started feeling sick, and I started getting sicker and sicker and sicker,” Gates recounted. “I was literally throwing up four, five times a day and I thought, ‘I can’t do this.’ So that’s it.” The constant nausea led him to discontinue the medication despite its potential benefits.

The Rise of Semaglutide-Based Drugs

Despite Gates’ personal struggles, semaglutide-based drugs like Ozempic and Wegovy have surged in popularity. These medications, produced by Novo Nordisk, are being heralded as solutions to the growing global challenges of obesity and type 2 diabetes. They have received endorsements from celebrities such as Oprah Winfrey and Elon Musk, which has significantly boosted their cultural relevance and demand.

What Are Ozempic and Wegovy?

Ozempic and Wegovy both use semaglutide as their active ingredient but are approved for different uses. Ozempic is primarily used for lowering blood sugar and regulating insulin in type 2 diabetes, while Wegovy is approved for weight loss. Both have shown clinical success not only in weight loss but also in reducing the risk of cardiovascular events among people with obesity.

Side Effects and Warnings

While effective, these drugs can have significant side effects, as experienced by Gates. Common side effects include nausea, vomiting, and diarrhea. More serious side effects can occur, and these medications should only be used under medical supervision.

Global Pricing of Semaglutide

The cost of semaglutide varies widely around the world:

  • United States: $800 to $900 USD per month for Ozempic or Rybelsus.
  • Canada: $400 to $480 USD per month.
  • United Kingdom: Approximately $100 USD per month.
  • Australia: $80 to $100 USD per month.
  • India: $280 to $480 USD per month for Rybelsus, Saxenda, Wegovy and Ozempic.

For more detailed information on prices, visit:

The Investment Case for Novo Nordisk

Novo Nordisk, the manufacturer of these drugs, has seen a substantial financial performance. The company claims an 85% share of the global obesity care market, with profits jumping 51% in recent annual results. This success has solidified its status as Europe’s most valuable company.

The Impact of Celebrity Endorsements

Celebrity endorsements have played a significant role in the popularity of semaglutide. High-profile users have helped propel these medications into the cultural zeitgeist, contributing to their status as “viral drugs.” However, this rapid popularity has also led to supply shortages and has raised concerns about the misuse of these drugs by individuals who do not meet the medical criteria for their use.

Conclusion

Josh Gates’ experience with semaglutide underscores the potential benefits and significant side effects of this medication. While it has proven effective for many, it is crucial to use it under medical guidance and be aware of the possible adverse effects. The high cost in the US contrasts sharply with more affordable options in countries like India, emphasizing the importance of exploring international sources for medication.

For further information and to explore purchasing options, visit:

By understanding these factors, patients can make informed decisions about their treatment and manage their health more effectively.

Harvoni Treatment Approved for Children

The Food and Drug Administration (FDA) has approved ledipasvir 90mg sofosbuvir 400mg for hepatitis C virus genotypes 1, 4, 5, or 6 for children patients twelve years and older. They child patients must weigh 77 pounds or 35Kg. Harvoni or generic Harvoni can be used to treat children that have cirrhosis or with mild cirrhosis.

harvoni is apparoved to treat HCV for child patients

Direct Acting Antivirals (DAAs) have helped millions around the world get cured from hepatitis C. Gilead Sciences first released the hepatitis C treatment back in 2013. The key ingredient that Gilead Sciences has provided hepatitis C patients around the world is Sofosbuvir.

Although the price of Sofosbuvir is not expensive, however, it has cost tax payers and the US government in billions of dollars to treat hepatitis C patients.

A few states have actually went bankrupt due to treating hep C patients on Medicare and Medicaid. By law a state must provide access to treatment if the treatment is available, regardless of cost. The cost of this blockbuster drug, Sovaldi, sofosbuvir 400mg, was $84,000. One tablet cost $1000. The treatment is for 12 weeks or 84 days.